We are live on
!
Find out more
OCA
Octagon Capital Advisors Portfolio holdings
AUM
$904M
1-Year Est. Return
737.04%
This Fund
S&P 500
This Quarter
Est. Return
+3.85%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$406M
AUM Growth
-$76.7M
(-16%)
Cap. Flow
-$39.6M
Cap. Flow
% of AUM
-9.76%
Top 10 Holdings %
Top 10 Hldgs %
73.39%
Holding
37
New
3
Increased
6
Reduced
12
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$19.1M |
| 2 |
Cytek Biosciences
CTKB
|
+$11.8M |
| 3 |
BridgeBio Pharma
BBIO
|
+$10.1M |
| 4 |
Celldex Therapeutics
CLDX
|
+$9.38M |
| 5 |
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
|
+$7.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zai Lab
ZLAB
|
+$19.4M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$14.1M |
| 3 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$12.9M |
| 4 |
Curis
CRIS
|
+$10.1M |
| 5 |
Vera Therapeutics
VERA
|
+$7.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.28% |
| 2 | Financials | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NBP
1
NovaBridge Biosciences American Depositary Shares
NBP
$205M
| $55.4M | 13.64% |
764,461
-178,695
| -19% | -$12.9M |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $52.6M | 12.95% |
1,595,911
+339,646
| +27% | +$19.1M |
|
|
3
Celldex Therapeutics
CLDX
$2.77B
| $41.1M | 10.12% |
761,398
+200,000
| +36% | +$9.38M |
|
4
Arcus Biosciences
RCUS
$3.57B
| $33.8M | 8.33% |
970,164
+210,000
| +28% | +$6.54M |
|
|
5
BridgeBio Pharma
BBIO
$16.5B
| $26.7M | 6.57% |
569,414
+188,486
| +49% | +$10.1M |
|
6
4D Molecular Therapeutics
FDMT
$526M
| $22.4M | 5.52% |
831,267
| – | – |
|
7
Gossamer Bio
GOSS
$66.5M
| $19M | 4.68% |
1,513,138
+100,000
| +7% | +$921K |
|
|
8
Curis
CRIS
$9.53M
| $18M | 4.42% |
5,737
-3,220
| -36% | -$10.1M |
|
9
Century Therapeutics
IPSC
$381M
| $15.2M | 3.73% |
602,623
+199,100
| +49% | +$5.39M |
|
10
Arvinas
ARVN
$518M
| $13.8M | 3.41% |
168,500
-10,000
| -6% | -$884K |
|
|
11
Vera Therapeutics
VERA
$2.54B
| $12.1M | 2.97% |
696,126
-436,545
| -39% | -$7.8M |
|
|
RNAM
12
DELISTED
Avidity Biosciences
RNAM
| $11M | 2.71% |
446,641
| – | – |
|
|
13
Cytek Biosciences
CTKB
$576M
| $10.7M | 2.64% |
+500,000
| New | +$11.8M |
|
14
Dyne Therapeutics
DYN
$4.04B
| $9.48M | 2.33% |
583,649
| – | – |
|
|
CNTB
15
Connect Biopharma Holdings
CNTB
$135M
| $7.79M | 1.92% |
326,143
-47,349
| -13% | -$1.07M |
|
16
Stoke Therapeutics
STOK
$1.82B
| $7.55M | 1.86% |
296,822
| – | – |
|
|
OMGA
17
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $6.98M | 1.72% |
+370,279
| New | +$7.1M |
|
18
Cardiff Oncology
CRDF
$64.3M
| $6.54M | 1.61% |
982,753
| – | – |
|
|
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $4.74M | 1.17% |
200,000
| – | – |
|
|
AMAM
20
DELISTED
Ambrx Biopharma Inc
AMAM
| $4.72M | 1.16% |
350,000
-100,000
| -22% | -$1.8M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.5M | 1.11% |
277,057
-402,979
| -59% | -$4.39M |
|
|
NGM
22
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $4.2M | 1.04% |
200,000
| – | – |
|
23
MoonLake Immunotherapeutics
MLTX
$1.59B
| $3.95M | 0.97% |
400,000
| – | – |
|
|
IMA
24
ImageneBio Inc
IMA
$63.1M
| $3.47M | 0.85% |
22,917
-10,416
| -31% | -$1.51M |
|
25
Monte Rosa Therapeutics
GLUE
$1.92B
| $3.34M | 0.82% |
150,000
-88,045
| -37% | -$2.52M |
|
Similar funds
AIC
AOWM
SWM
EI
PIP
PSCM
EWM
PC
Octagon Capital Advisors's Q3 2021 Portfolio in Review
As of Q3 2021, Octagon Capital Advisors held 37 positions worth $406M, down 16% from $483M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Octagon Capital Advisors withdrew a net $39.6M in Q3 2021, closing 7 positions and reducing 12 holdings. Its most notable exit was Zai Lab, an estimated $19.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.
Against the trend, Octagon Capital Advisors opened a new position in Cytek Biosciences worth $10.7M.
- Octagon Capital Advisors's largest Q3 2021 buy was Cytek Biosciences: 500,000 shares worth $10.7M.
- Octagon Capital Advisors added most to Apellis Pharmaceuticals in Q3 2021, an estimated $19.1M increase.
- Octagon Capital Advisors's biggest Q3 2021 reduction was NovaBridge Biosciences American Depositary Shares, cutting an estimated $12.9M.
- Octagon Capital Advisors fully exited Zai Lab in Q3 2021, selling an estimated $19.4M.
- Octagon Capital Advisors's ten largest holdings make up 73% of its $406M portfolio in Q3 2021.
- Octagon Capital Advisors opened 3 new positions and closed 7 in Q3 2021.
- Octagon Capital Advisors's portfolio value fell 16% quarter-over-quarter to $406M.
Based on Octagon Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.